TNhYP218 CAR T Cells

Phase 1

NNational Cancer Institute (NCI)

TNhYP218 CAR T Cells is one of 24 therapeutic programs targeting Mesothelioma. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

MesotheliomaRecruiting

MesotheliomaPhase 1

Recruiting

Competition

Competitive Landscape

26 competitors in Mesothelioma

#DrugCompanyPhaseTrials

Lynparza

Afinitor

Iressa

Nexavar

Zometa

Beleodaq

AAcrotech Biopharma Inc.

Yondelis

Photofrin

PPinnacle Biologics Inc.

Mitosol

Zolinza

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Approved

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2044

Phase 1Recruiting

Mesothelioma

NCT06885697

Clinical

Trials by Indication[1]

Mesothelioma1 trial

Phase 1 Study With Dose Expansion of the Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including Mesothelioma

Recruiting·NNational Cancer Institute (NCI)·Phase 1·NCT06885697·100 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for TNhYP218 CAR T Cells. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for TNhYP218 CAR T Cells. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — National Cancer Institute (NCI) company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 1[1]
Company: NNational Cancer Institute (NCI)

TNhYP218 CAR T Cells

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q2 2044

Trials by Indication[1]

Mesothelioma1 trial

References

Drug Info

Quick Facts

Related News